Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19

BACKGROUND: The open-label RECOVERY study reported improved survival in hospitalized, SARS-CoV-2 seronegative patients treated with casirivimab and imdevimab (CAS + IMD). METHODS: In this phase 1/2/3, double-blind, placebo-controlled trial conducted prior to widespread circulation of Delta and Omicr...

Descripción completa

Detalles Bibliográficos
Autores principales: Somersan-Karakaya, Selin, Mylonakis, Eleftherios, Menon, Vidya P, Wells, Jason C, Ali, Shazia, Sivapalasingam, Sumathi, Sun, Yiping, Bhore, Rafia, Mei, Jingning, Miller, Jutta, Cupelli, Lisa, Forleo-Neto, Eduardo, Hooper, Andrea T, Hamilton, Jennifer D, Pan, Cynthia, Pham, Viet, Zhao, Yuming, Hosain, Romana, Mahmood, Adnan, Davis, John D, Turner, Kenneth C, Kim, Yunji, Cook, Amanda, Kowal, Bari, Soo, Yuhwen, DiCioccio, A Thomas, Geba, Gregory P, Stahl, Neil, Lipsich, Leah, Braunstein, Ned, Herman, Gary A, Yancopoulos, George D, Weinreich, David M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384575/
https://www.ncbi.nlm.nih.gov/pubmed/35895508
http://dx.doi.org/10.1093/infdis/jiac320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384575/
https://www.ncbi.nlm.nih.gov/pubmed/35895508
http://dx.doi.org/10.1093/infdis/jiac320

Ejemplares similares